ATE176401T1 - Liposomale prostaglandinformulierungen - Google Patents

Liposomale prostaglandinformulierungen

Info

Publication number
ATE176401T1
ATE176401T1 AT92401262T AT92401262T ATE176401T1 AT E176401 T1 ATE176401 T1 AT E176401T1 AT 92401262 T AT92401262 T AT 92401262T AT 92401262 T AT92401262 T AT 92401262T AT E176401 T1 ATE176401 T1 AT E176401T1
Authority
AT
Austria
Prior art keywords
prostagland
liposomal
formulations
prostaglandin
cell activation
Prior art date
Application number
AT92401262T
Other languages
English (en)
Inventor
Marc J Ostro
Original Assignee
Liposome Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Liposome Co Inc filed Critical Liposome Co Inc
Application granted granted Critical
Publication of ATE176401T1 publication Critical patent/ATE176401T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1277—Preparation processes; Proliposomes
    • A61K9/1278—Post-loading, e.g. by ion or pH gradient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Dispersion Chemistry (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AT92401262T 1991-05-07 1992-05-06 Liposomale prostaglandinformulierungen ATE176401T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US69731491A 1991-05-07 1991-05-07
US87620092A 1992-04-30 1992-04-30

Publications (1)

Publication Number Publication Date
ATE176401T1 true ATE176401T1 (de) 1999-02-15

Family

ID=27105991

Family Applications (1)

Application Number Title Priority Date Filing Date
AT92401262T ATE176401T1 (de) 1991-05-07 1992-05-06 Liposomale prostaglandinformulierungen

Country Status (15)

Country Link
EP (1) EP0512916B1 (de)
JP (1) JPH06507417A (de)
KR (1) KR100300772B1 (de)
AT (1) ATE176401T1 (de)
AU (1) AU664704B2 (de)
CA (1) CA2108788C (de)
DE (1) DE69228332T2 (de)
DK (1) DK0512916T3 (de)
ES (1) ES2128343T3 (de)
FI (1) FI934913A7 (de)
GR (1) GR3029641T3 (de)
IE (1) IE921461A1 (de)
MX (1) MX9202131A (de)
NO (1) NO306048B1 (de)
WO (1) WO1992019243A1 (de)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5925375A (en) * 1987-05-22 1999-07-20 The Liposome Company, Inc. Therapeutic use of multilamellar liposomal prostaglandin formulations
US5811118A (en) * 1987-05-22 1998-09-22 The Liposome Company, Inc. Methods of treatment using unilamellar liposomal arachidonic acid metabolite formulations
US5882678A (en) * 1990-01-12 1999-03-16 The Liposome Co, Inc. Interdigitation-fusion liposomes containing arachidonic acid metabolites
US5629287A (en) * 1991-01-18 1997-05-13 University College London Depot formulations
US5610148A (en) * 1991-01-18 1997-03-11 University College London Macroscopically oriented cell adhesion protein for wound treatment
EP0679088B1 (de) 1992-09-29 2002-07-10 Inhale Therapeutic Systems Pulmonale abgabe von aktiven fragmenten des parathormons
US5853755A (en) * 1993-07-28 1998-12-29 Pharmaderm Laboratories Ltd. Biphasic multilamellar lipid vesicles
CA2175057A1 (en) * 1993-11-04 1995-05-11 Robert P. Lenk Multilamellar liposomal arachidonic acid metabolite formulations
DE69416425T2 (de) * 1993-11-16 1999-06-10 The Liposome Co.,Inc., Princeton, N.J. Arachidonsäuremetaboliten enthaltende interdigitations-fusions-liposomen
WO1995018620A1 (en) * 1994-01-11 1995-07-13 The Liposome Company, Inc. Treatment using arachidonic acid metabolite and particulate formulations
ATE416755T1 (de) 1994-03-07 2008-12-15 Nektar Therapeutics Verfahren und zusammensetzung für die pulmonale darreichung von insulin
US5718917A (en) * 1995-12-15 1998-02-17 Harvard Scientific Corporation PGE-1 containing lyophilized liposomes for use in the treatment of erectile dysfunction
US6001333A (en) * 1997-09-12 1999-12-14 See; Jackie R. Methods of preparing micro encapsulated agents for use in the detection of tumors by CT imaging
US20060165606A1 (en) 1997-09-29 2006-07-27 Nektar Therapeutics Pulmonary delivery particles comprising water insoluble or crystalline active agents
US6565885B1 (en) 1997-09-29 2003-05-20 Inhale Therapeutic Systems, Inc. Methods of spray drying pharmaceutical compositions
US6309623B1 (en) 1997-09-29 2001-10-30 Inhale Therapeutic Systems, Inc. Stabilized preparations for use in metered dose inhalers
US7871598B1 (en) 2000-05-10 2011-01-18 Novartis Ag Stable metal ion-lipid powdered pharmaceutical compositions for drug delivery and methods of use
PT1458360E (pt) 2001-12-19 2011-07-13 Novartis Ag Derivados de indole como agonistas do recetor s1p1
US8697120B2 (en) 2006-05-01 2014-04-15 Johns Hopkins University Method and use of nano-scale devices for reduction of tissue injury in ischemic and reperfusion injury
TWI728255B (zh) * 2017-07-24 2021-05-21 國邑藥品科技股份有限公司 包含弱酸藥物之脂質體組成物及其用途

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS58222014A (ja) * 1982-06-18 1983-12-23 Taisho Pharmaceut Co Ltd プロスタグランジンｅ↓１脂肪乳剤
EP0153858A3 (de) * 1984-02-29 1985-12-11 The Upjohn Company Therapeutische Anwendung von Protaglandinen
US4820732A (en) * 1985-10-04 1989-04-11 The Upjohn Company Method and compositions for reducing dysfunction in angioplasty procedures
US5082664A (en) * 1987-05-22 1992-01-21 The Liposome Company, Inc. Prostaglandin-lipid formulations

Also Published As

Publication number Publication date
DE69228332T2 (de) 1999-09-16
GR3029641T3 (en) 1999-06-30
EP0512916A3 (en) 1992-12-09
FI934913L (fi) 1993-11-05
AU664704B2 (en) 1995-11-30
DE69228332D1 (de) 1999-03-18
FI934913A0 (fi) 1993-11-05
NO306048B1 (no) 1999-09-13
EP0512916B1 (de) 1999-02-03
KR100300772B1 (ko) 2001-10-22
JPH06507417A (ja) 1994-08-25
MX9202131A (es) 1993-04-01
AU2027392A (en) 1992-12-21
NO934016D0 (no) 1993-11-05
WO1992019243A1 (en) 1992-11-12
IE921461A1 (en) 1992-11-18
ES2128343T3 (es) 1999-05-16
DK0512916T3 (da) 1999-09-20
EP0512916A2 (de) 1992-11-11
CA2108788A1 (en) 1992-11-12
CA2108788C (en) 2003-09-30
FI934913A7 (fi) 1993-11-05
NO934016L (no) 1993-11-05

Similar Documents

Publication Publication Date Title
ATE176401T1 (de) Liposomale prostaglandinformulierungen
DE58906076D1 (de) Benzophenonderivate und deren Herstellung.
FI890282A0 (fi) Menetelmä terapeuttisesti käyttökelpoisten 23,24-didehydro-25-hydroksikalsiferolijohdannaisten valmistamiseksi
FI891389A0 (fi) Menetelmä makeutusaineen valmistamiseksi
FI880815A7 (fi) Menetelmä uusien terapeuttisesti käyttökelpoisten 5-okso-4,5-dihydro-imidatso/1,5-a/kinatsoliinijohdannaisten valmistamiseksi
FI981710L (fi) Terapeuttisesti käyttökelpoiset 1,2,3,3a,8,8a-heksahydro-1,3a,8-trimetyylipyrrolo/2,3-b/indol-5-yylijohdannaiset
DE3577722D1 (de) Derivat des adult-t-zell-leukemiavirus-antigenpeptids.
FI892908L (fi) Menetelmä uusien terapeuttisesti käyttökelpoisten imidatso/1,5-a/kinoksaliinijohdannaisten valmistamiseksi
FI892684A0 (fi) Menetelmä terapeuttisesti aktiivisten 4-okso-imidatso/1,5-a/kinoksaliinijohdannaisten valmistamiseksi
FI102066B1 (fi) Menetelmä farmakologisesti aktiivisen 2,5,6,7-tetranor-4,8-inter-m-fenyleeni-PGI2-johdannaisen valmistamiseksi sekä välituote
FI900145A0 (fi) Menetelmä farmaseuttisesti käyttökelpoisten 1,1-diokso-kefem-4-karbotiolihappojohdannaisten valmistamiseksi
FI873750A0 (fi) Anordning foer detektering av en begynnande uppvisningsansats i ett ark under framstaellning av arket.
FI83875B (fi) Ett nytt foerfarande foer framstaellning av 4-deoxipyrido/1'2':1,2/imidazo/5,4-c/rifamyciner.
FI890478A7 (fi) Menetelmä uusien terapeuttisesti käyttökelpoisten 4-okso-4H-pyrido/1,2-a/pyrimidiini-3-karboksamidijohdannaisten valmistamiseksi
FI89047C (fi) Foerfarande foer framstaellning av terapeutiskt anvaendbara 5-aryl-2,4-dialkyl-3h-1,2,4-triazol-3-tioner
GB2207574B (en) High gain amplifier using two current mirrors
FI891807A7 (fi) Menetelmä terapeuttisesti aktiivisten oktahydropyrrolo-pyratsino/2,1-i/indol-2-oni-johdannaisten valmistamiseksi
FI91526B (fi) Menetelmä uusien terapeuttisesti käyttökelpoisten 3-aryyli-5-alkyylisulfinyyli- ja sulfonyyli-4H-1,2,4-triatsolien valmistamiseksi
FI893121A0 (fi) Menetelmä farmakologisesti aktiivisten 6,21-dimetyyli-19-norprogesteronijohdannaisten valmistamiseksi
FI931891A0 (fi) Menetelmä uusien terapeuttisesti käyttökelpoisten 7,8-dihydroksi-1H-imidatso- ja pyratsolo/3,4-f/kinoksaliinijohdannaisten valmistamiseksi
FI96855B (fi) Menetelmä terapeuttisesti aktiivisten 2-metoksikarbonyylisubstituoitujen N,N'-di(trimetoksibentsoyyli)piperatsiinijohdannaisten valmistamiseksi
DE69331579D1 (de) Herstellung von 2d-arrays
FI882299L (fi) Saett och anordning foer mammografisk stereotaktisk punktion av patologiska foeraendringar i dett kvinnliga broestet.
FI912247A0 (fi) Menetelmä terapeuttisesti käyttökelpoisten pyrrolo/2,3-b/indoliketonijohdannaisten valmistamiseksi
GR880100196A (el) Υποκατεστημενα 1,3-διοξολαν-και 1,3-διοξαν-παραγωγα,μεθοδοι για την παρασκευη τους και η χρηση τους

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
REN Ceased due to non-payment of the annual fee